

## **SURVEY SCHEDULE 2026**

### Screening tests & Assays (Level 1 and 2)

<b>Survey</b>	<b>274 &amp; 1274</b>	<b>275 &amp; 1275</b>	<b>276 &amp; 1276</b>	<b>277 &amp; 1277</b>
<b>Planned Distribution</b>	6 January	21 April	21 July	20 October

### Direct Oral Anticoagulant (DOAC) Assay

<b>Survey</b>	<b>S38</b>	<b>S 2602</b>	<b>S 2603</b>	<b>S 2604</b>
<b>Planned Distribution</b>	24 February	9 June	8 September	24 November

### Lupus Anticoagulant

<b>Survey</b>	<b>S27</b>	<b>S28</b>
<b>Planned Distribution</b>	28 July	19 January 27

### Additional/Supplementary Exercises

#### FVIII Inhibitor – ADAMTS – FXIII – HIT – FVIII – FIX – Emicizumab

<b>Survey</b>	<b>Survey</b>	<b>Survey</b>	<b>Survey</b>	<b>Survey</b>
<b>Planned Distribution</b>	6 January	21 April	21 July	20 October

### Homocysteine Screening Programme

<b>Survey</b>	<b>Survey</b>	<b>Survey</b>	<b>Survey</b>	<b>Survey</b>
<b>Planned Distribution</b>	21 April	21 July	20 October	26 January 27

### Molecular Genetics of Thrombophilia (FV Leiden G20210A mutation)

<b>Survey</b>	<b>Survey</b>	<b>Survey</b>	<b>Survey</b>
<b>Planned Distribution</b>	10 January	7 July	10 November